Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Gives Pharsight the Boot; Company Plans Not to Appeal

NEW YORK, Nov. 4 - The Nasdaq exchange will delist Pharsight this Friday for failing to keep its share price above $1 for 120 days, the company said today.


Shares in Pharsight last traded at or above $1 on Aug. 21, according to the Nasdaq. Company officials, which will not challenge the Nasdaq decision, were not immediately available for comment.


Struggling for breathing room, Pharsight in mid-July kicked off a company-wide restructuring plan designed to save as much as $3 million in annual operating costs. The plan called for the creation of three distinct business units and a 15-percent reduction in headcount.


One week later, the company appeared to have gained some traction. Fiscal first-quarter net loss narrowed after expenses were trimmed by $2.6 million, including a $500,000 cut in R&D spending, atop a 26-percent jump in total revenue.


But over the ensuing three months, despite securing $4.4 million in the second round of a two-round private-equity tranche, Pharsight saw its luck start to fizzle. Revenue for the period ended Sept. 30 fell to $3.3 million from $3.7 million one year ago, and R&D spending nose-dived to just $900,000 from $1.7 million year over year, Pharsight said.


The company, which held around $13.4 million in cash, cash equivalents, and short-term investments as of Sept. 30, now said it wouldn't break even by next summer. Pharsight will "acieve this milestone at a later date," said Michael Perry, president and CEO.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.